Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171777 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
- 20
- Study locations
NCT05171777: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
NCT05171777 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 179 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05171777, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).
Primary Outcome
Participants preference was assessed based on the Question 1 of PPQ. Question 1 (All things considered, which route of administration did you prefer?) asks participants to report their preference for the route of administration (IV, SC, or no preference). A point estimate with associated 95% CI for the percentage of participants who preferred atezolizumab SC was calculated. Participants experiencing any of the following events: treatment withdrawal prior to eligibility for PPQ, or death without
Conditions Studied
Interventions
- DRUG Atezolizumab
Study Locations (20)
Other
- Fundación CENIT para la Investigación en Neurociencias - Buenos Aires
- CEMIC - Buenos Aires
- Centro Oncologico Korben - Ciudad Autonoma Buenos Aires
- OrlandiOncología - Santiago
- Clinica CIMCA - San José
- ICIMED Instituto de Investigación en Ciencias Médicas - San José
- Oulun yliopistollinen sairaala (OYS) - Oulu
- Tampereen yliopistollinen sairaala (TAYS) - Tampere
- Turun yliopistollinen keskussairaala (TYKS) - Turku
- Vaasan Keskussairaala - Vaasa
Rio Grande do Sul
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda - Ijuí
- Hospital das Clinicas - UFRGS - Porto Alegre
- Hospital Nossa Senhora da Conceicao - Porto Alegre
Ontario
- Royal Victoria Regional Health Centre - Barrie
- Sault Area Hospital - Sault Ste. Marie
New Jersey
- New Jersey Hematology Oncology Associates LLC - Brick
Ohio
- Tri County Hematologyoncology - Massillon
Oregon
- Asante Rogue Regional Medical Center - Medford
Pennsylvania
- UPMC - Hillman Cancer Center - Pittsburgh
São Paulo
- Instituto do Cancer do Estado de Sao Paulo - ICESP - São Paulo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
What the finished NCT05171777 record still lists
NCT05171777 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab is the first listed.
NCT05171777 names 20 study sites across 8 states, led by Other, Rio Grande do Sul, Ontario.
Frequently Asked Questions
What is clinical trial NCT05171777 about?
NCT05171777 is a clinical study titled "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer". This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemother...
What is the current status of trial NCT05171777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2022-04-04. Estimated completion is 2024-10-25.
What conditions does trial NCT05171777 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05171777?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT05171777?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05171777 being conducted?
This trial has 20 study locations across New Jersey, Ohio, Oregon, Pennsylvania, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05171777's enrollment target sits among peer trials
179 179th of 454 higher than 275 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI